Ubiquitin reduces contusion volume after controlled cortical impact injury in rats.
Recent data suggest that ubiquitin has anti-inflammatory properties and therapeutic potential after severe trauma and brain injuries. However, direct evidence for its neuroprotective effects has not yet been provided. We hypothesized that ubiquitin treatment is neuroprotective, and thus reduces brain edema formation and cortical contusion volume after closed traumatic brain injuries. To test this hypothesis, a focal cortical contusion was induced using a controlled cortical impact (CCI) model in Sprague-Dawley rats. Animals (n = 27) were randomized to either 1.5 mg/kg ubiquitin or vehicle (placebo) intravenously within 5 min after CCI. Blood pressure, arterial blood gases (ABG) and intracranial pressure (ICP) were monitored. Ubiquitin serum and cerebrospinal fluid levels were measured by ELISA. Brain water content was quantified gravimetrically after 24 h and cerebral contusion volume was determined in triphenyltetrazolium-chloride stained brains after 7 days. All animals recovered to normal activity. ICP and cerebral perfusion pressures were normal at the end of the observation period. Ubiquitin serum and CSF levels at 24 h and 7 days after CCI were similar in both groups. With ubiquitin brain water content of the injured hemisphere was slightly lower (n = 6/group; 79.97 +/- 0.29% vs. 81.11 +/- 0.52%; p = 0.08). Cortical contusion volume was significantly lower with ubiquitin (n = 7-8/group; 32.88 +/- 2.1 mm(3) vs. 43.96 +/- 4.56 mm(3); p = 0.025). This study shows that ubiquitin treatment after brain injury has direct neuroprotective effects, as demonstrated by improved brain morphology 7 days after brain injury. In connection with its beneficial effects in our previous studies, these data suggest ubiquitin as a promising candidate protein therapeutic for the treatment of brain injuries.
Griebenow
Martin
M
Department of Neurosurgery, Charité, Virchow Medical Center, Humboldt University, Berlin, Germany.
Casalis
Pablo
P
Woiciechowsky
Christian
C
Majetschak
Matthias
M
Thomale
Ulrich-Wilhelm
UW
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001929:Brain Edema / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D001930:Brain Injuries / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D004797:Enzyme-Linked Immunosorbent Assay; D016489:Head Injuries, Closed / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D007427:Intracranial Pressure / Q000187:drug effects; D008297:Male; D018696:Neuroprotective Agents / Q000097:blood / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D025801:Ubiquitin / Q000032:analysis / Q000627:therapeutic use*
D018696:Neuroprotective Agents; D025801:Ubiquitin